Skip to main content
. 2013 Jan 13;17(1):13–21. doi: 10.1007/s11102-012-0460-2

Fig. 1.

Fig. 1

IGF-I levels after 12 months’ treatment with lanreotide depot (n = 87). The ‘Combination/other’ group comprises patients who received injections from any combination of injectors [self, partner, (HCP)]